Zosurabalpin : New Class Of Antibiotics
Researchers have identified a new class of antibiotics, specifically zosurabalpin, with the potential to combat drug-resistant bacterium Acinetobacter baumannii.
- This antibiotic was found to be effective against CRAB (carbapenem-resistant Acinetobacter baumannii)-induced pneumonia and sepsis in mouse models.
- Zosurabalpin, a drug candidate, was developed through the optimization of a tethered macrocyclic peptide (MCP) that selectively kills A. baumannii.
- The antibiotic’s unique mode of action involves inhibiting the transport of lipopolysaccharide (LPS), an essential process for creating the outer-membrane structure of Gram-negative bacteria.
- Zosurabalpin blocks LPS transport, leading to the abnormal build-up of LPS in the cell and the subsequent death of the bacterium.
- Gram-negative bacteria have a thin peptidoglycan layer in the cell wall, which is sandwiched between two lipid membranes, giving them a complex structure.
- This outer membrane acts as a barrier, making them more resistant to antibiotics.